Regulation of survivin expression by IGF-1/mTOR signaling

Oncogene

Volumn 26, Issue 19, 2007, Pages 2678-2684

  Vaira, V ^a,b   Lee, C W ^a   Goel, H L ^a   Bosari, S ^b   Languino, L R ^a   Altieri, D C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

IGF 1; mTOR; Prostate cancer; Rapamycin; Survivin

Indexed keywords

CYCLOHEXIMIDE; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PACLITAXEL; RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; SURVIVIN;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTEIN KINASES; RECEPTOR, IGF TYPE 1; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA STABILITY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 34247474846     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210094     Document Type: Article

References (38)

1. Altieri DC. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
2. Altieri DC. (2006). Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482.
3. Amaravadi R, Thompson CB. (2005). The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624.
4. Ambrosini G, Adida C, Altieri DC. (1997). A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
5. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
6. Cory S, Adams JM. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656.
7. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM et al. (2004). Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyl-transferase I inhibitor-induced apoptosis. Oncogene 23: 706-715.
8. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
9. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F et al. (2003). Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101: 278-285.
10. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. (2004). Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
11. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M et al. (2003). Fibronectin protects prostate cancer cells from tumor necrosis factor. J Biol Chem 278: 50402-50411.
12. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y et al. (2005). Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33-44.
13. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
14. Hay N. (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
15. Hengartner MO. (2000). The biochemistry of apoptosis. Nature 407: 770-776.
16. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247-3257.
17. Holcik M, Yeh C, Korneluk RG, Chow T. (2000). Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19: 4174-4177.
18. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. (2006). Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71: 1435-1448.
19. Kane LP, Mollenauer MN, Xu Z, Turck CW, Weiss A. (2002). Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 22: 5962-5974.
20. Kane LP, Shapiro VS, Stokoe D, Weiss A. (1999). Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9: 601-604.
21. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L et al. (2003). Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9: 4914-4925.
22. Levine AJ, Feng Z, Mak TW, You H, Jin S. (2006). Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20: 267-275.
23. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S et al. (1999). Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1: 461-466.
24. Li F, Altieri DC. (1999). Transcriptional analysis of human survivin gene expression. Biochem J 344(Part 2): 305-311.
25. Li S, Resnicoff M, Baserga R. (1996). Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem 271: 12254-12260.
26. Majumder PK, Sellers WR. (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
27. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622.
28. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S et al. (2005). Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102: 5998-6003.
29. cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97: 13103-13107.
30. Reed JC. (2003). Apoptosis-targeted therapies for cancer. Cancer Cell 3: 17-22.
31. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B, Baserga R. (1999). Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 72: 294-310.
32. Salvesen GS, Duckett CS. (2002). Apoptosis: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410.
33. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T et al. (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612.
34. Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M et al. (2006). IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107: 669-678.
35. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. (2005). Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310: 1499-1504.
36. Wullschleger S, Loewith R, Hall MN. (2006). TOR signaling in growth and metabolism. Cell 124: 471-484.
37. Yang S, Lim M, Pham LK, Kendall SE, Reddi AH, Altieri DC et al. (2006). Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res 66: 4285-4290.
38. Zhang M, Latham DE, Delaney MA, Chakravarti A. (2005). Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482.